⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL364 | 1.00 | — | — | |
| SCHEMBL29214507 | 0.97 | CYP2D6 (0.55) | — | |
| Bromide SCHEMBL20591841 | 0.97 | CYP2D6 (0.55) | — | |
| Water SCHEMBL28870924 | 0.97 | CYP2D6 (0.55) | — | |
| Bromide SCHEMBL2900871 | 0.97 | CYP2D6 (0.55) | — | |
| Hydrochloric Acid SCHEMBL9114387 | 0.97 | CYP2D6 (0.55) | — | |
| SCHEMBL6260224 | 0.97 | CYP2D6 (0.55) | — | |
| Hydrochloric Acid SCHEMBL31308676 | 0.97 | CYP2D6 (0.55) | — | |
| Bromide SCHEMBL3252964 | 0.97 | CYP2D6 (0.55) | — | |
| Hydrochloric Acid SCHEMBL3529241 | 0.97 | CYP2D6 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-10 | — | — | US | disclosed |
| CN-117279632-A | TAAR1 and serotonin modulators, pharmaceutical compositions thereof, and methods of use | 赛诺维信制药公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20220387428-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |